2024 Employee Champions
Congratulations to our 2024 Working For Cures Champions. As in years past, these honorees go above and beyond to advance science and support the work our industry does for patients.
This year’s champions have conducted facility tours with members of Congress, elevated minority voices, and raised awareness about barriers to care that patients face.
Mike Edmondson
Vice President | Amgen
Mike is a leader in Amgen’s Black Employee Resource Group. He partners with community-based organizations to advance public health priorities and is actively involved with the Congressional Black Caucus. He regularly attends CBC events and champions Amgen's work to build partnerships with influential policymakers. Additionally, he is a tireless advocate for elevating colleagues within Amgen who advance health equity.
Liv Gagne
Lead, Patient Partnerships | Astellas
Liv has raised the profile of women’s health at midlife, highlighting the importance of menopause awareness and access to care. To achieve this, she’s engaged with advocacy groups, developed educational materials and has advocated for meaningful policy changes in Congress and state legislatures.
Shaun Venable
Head of Corporate Communications at Biogen’s Research Triangle Park (RTP) Campus | Biogen
Shaun partners with Biogen’s Public Policy & Government Affairs team on legislative advocacy and community engagement. She has helped host several congressional and state policymakers at Biogen’s North Carolina site and participated in a fly-in event in Washington, DC.
Neil Bence
Senior Vice President, Head of Protein Homeostasis Thematic Research Center | Bristol Myers Squibb
As the former BMS San Diego site lead, Neil conducted campus point facility tours with members of Congress. He also participated in discussions on IP rights, reinvestment and drug pricing.
Ram Gupta
Director, National Accounts | Genmab
Ram educates Genmab's government affairs team about how patients have to navigate obstacles from health plans, hospitals, pharmacies and more. Her understanding of the health care market and the patient experience helps Genmab determine its policy priorities.
Dr. Jim Hartke
Vice President, Nonclinical Safety and Pathobiology | Gilead Sciences
Jim closely worked with the Gilead federal government affairs team to engage federal lawmakers and regulatory officials, highlighting concerns over a recent policy that was exacerbating shortages in R&D resources. He was able to resolve the issue so Gilead could continue its important work. His efforts drew attention from national lawmakers, highlighting the impact supply chain issues can have on drug development in the United States.
John Capriotti
Sr. Director, Market Access, Contract Operations | GSK
John is an expert on the 340B program. He brings together a unique and highly valuable set of expertise and common-sense approach to how we approach the 340B Drug Discount Program. At the same time, he navigates the complex policies as they exist today, with an eye toward potential changes that could improve the program moving forward.
Pearl Pugh
President of Neuroscience | Johnson & Johnson
Pearl has long been an advocate in the mental health space, reducing the stigma surrounding mental health issues.
She has also taken a hands-on approach to supporting underserved populations and walked alongside street medicine physicians on Skid Row in Los Angeles, and her work has fostered compassion and understanding in the community.
Petr Vachal, Ph.D.
Associate Vice President, Discovery Chemistry | Merck
In the past year, Dr. Vachal spoke with 30 congressional offices about Merck's pioneering work on engineered cyclic peptides. Using 3D printed models, he demonstrated the complex chemistry and unique potential of these molecules, which have the potential to revolutionize clinical outcomes and patient access.
Ian Hunt
Global Head of Scientific Engagement | Novartis
Ian collaborates with the Novartis US Public Affairs team, allowing the company to demonstrate its work and commitment to advancing unmet medical needs for patients across the globe. Ian and his team have met with key members of state legislatures across the United States.
Dr. Megan O’Meara
Head of Oncology Early-Stage Development | Pfizer
Megan has actively engaged with Pfizer’s US Policy & Government Relations colleagues to help educate congressional staffers on Pfizer’s oncology vision and strategy. Additionally, she serves as a member of Pfizer’s Political Contributions Policy Committee.
Dr. Jeffrey Stark
Vice President and Head, U.S. Medical Immunology | UCB
Jeff is a leader in the rheumatology community. He is also a fierce advocate for patient awareness and rights. He was instrumental in creating the HS Coalition, which helps enhance awareness and diagnosis of this chronic inflammatory skin condition.